Influence of proton pump inhibitors on clinical efficacy of chemotherapy for advanced gastric cancer

Abstract

Abstract:

AIM: Oxaliplatin combined with capecitabine (XELOX program) is the preferred chemotherapy regimen for patients with advanced gastric cancer. But, it remains uncertain whether extra administration of proton pump inhibitors (PPI) will influence the effect of capecitabine. This study investigates the influence of PPI on clinical efficacy of chemotherapy for advanced gastric cancer. METHODS: Fifty-four patients with advanced gastric cancer of the second affiliated hospital of Zhengzhou University from January 2014 to January 2016 were reviewed and analyzed. They were treated with XELOX regimen, i.e., oxaliplatin 130 mg/m2, continuous intravenous drip infusion for 2 h; capecitabine 1 000 mg/m2,po.,taking in the morning and evening within half an hour after a meal, D1-14. 21 d constitutes a cycle. Patients treated with proton pump inhibitor were observed as the observation group (24 cases) and without as the control group (30 cases). All patients received maximally eight cycles of chemotherapy. RESULTS:Twenty-three cases from the observation group were evaluable.The mean follow-up was 10.3 months;the median time to progression was 5.7 months (95% confidence interval,4.6-7.1 months); the median survival time was 10.2 months (95% confidence interval, 7.7-12.8 months). While twenty-eight cases from the control group 28 cases were evaluable.The median follow-up time was 11.0 months; the median time to progression was 6.1 months (95% confidence interval, 4.8-7.3 months); the median survival time was 11.1 months (95% confidence interval 8.3-13.1 months). CONCLUSION: Proton pump inhibitors increase the pH of gastric juice and affect the dissolution and absorption of capecitabine, which may further influence the therapeutic effect of XELOX on advanced gastric cancer.

Key words: gastric cancer, proton pump inhibitor, capecitabine

CLC Number:

R735

ZHAI Mengmeng, LI Zhigang, SHEN Jie, WANG Fengli, GU Ning, YANG Na. Influence of proton pump inhibitors on clinical efficacy of chemotherapy for advanced gastric cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 933-936.

References

［1］Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer［J］. Ann Oncol, 2011, 22(12): 2610-2615.
［2］Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know［J］. Drugs, 2003, 63(24): 2739-2754.
［3］Seo KW, Jeon T, Kim S, et al. Epidemiologic study of human epidermal growth factor receptor 2 expression in advanced/metastatic gastric cancer: an assessment of human epidermal growth factor receptor 2 status in tumor tissue samples of gastric and gastro-esophageal junction cancer［J］. J Gastric Cancer, 2017, 17(1): 52-62.
［4］林明生, 王常松. 中医药对胃癌术后化疗患者的辨治思路［J］. 长春中医药大学学报, 2015, 31(2): 278-280.
［5］田相国, 张春清. 门静脉高压并食管胃底静脉曲张出血的治疗策略［J］. 临床肝胆病杂志, 2015, 31(3): 354-356.
［6］Morgen CS, Sorensen TI. Obesity: global trends in the prevalence of overweight and obesity［J］. Nat Rev Endocrinol, 2014, 10(9): 513-514.
［7］Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy［J］? Clin Pharmacol Ther, 2012, 92(2): 203-213.
［8］McColl KE, Kennerley P. Proton pump inhibitors-differences emerge in hepatic metabolism［J］. Dig Liver Dis, 2002, 34(7): 461-467.
［9］Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine［J］. Clin Pharmacokinet, 2001, 40(2): 85-104.
［10］Hurlimann S, Michel K, Inauen W, et al. Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers［J］. Am J Gastroenterol, 1996, 91(6): 1173-1180.
［11］Ha VH, Ngo M, Chu MP, et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer［J］? J Oncol Pharm Pract, 2015, 21(3): 194-200.
［12］ Gursoy O, Memis D, Sut N. Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients: a randomized, double-blind, placebo-controlled study［J］. Clin Drug Investig, 2008, 28(12): 777-782.

[1]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[2]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[3]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[4]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[5]	JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi. AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
[6]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[7]	XU Guofang, GAO Pan, LIU Ping, LAI Yaowen, LI Guanghui, ZHAO Yue, ZHANG Yongling, LI Xiaosu, QI Qi. Effects of individual differences on the pharmacokinetics of capecitabine in cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 305-311.
[8]	WU Yi, ZHU Akao, SHAN Yuqiang, YING Rongchao, JIN Huicheng. Resveratrol regulates miR-409-3p/FKBP14 to inhibit the malignant biological processes of gastric cancer BGC823 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 968-975.
[9]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[10]	TIAN Dahao, LU Linming, ZHI Hui, ZHOU Jue, WANG Xiaoqing, JIANG Yuhua. AHVAC-I inhibits the proliferation in human primary gastric cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 505-511.
[11]	SHEN Cheng, YANG Nianzhao, WANG Minghai, WU Lisheng, ZHU Zhiqiang. Inhibiting RNA methylase NSUN2 reduce the invasion and migration of gastric cancer cell [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 380-386.
[12]	WANG Aijuan, GUO Yiyun, WANG Zhiqiu. Apatinib combined with capecitabine in the treatment of advanced triple-negative breast cancer as third-line therapy: An observational study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 433-439.
[13]	XU Guofang, GAO Pan, LIU Ping, ZHANG Xiaolei, JING Cui, ZHANG Cuicui, JING Huixia, LI Xiaosu, QI Qi. Bioequivalence of capecitabine tablets in cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1119-1124.
[14]	YIN Ziyi, WANG Feng, ZHAO Meng, ZHANG Tie, WANG Pilin. Effects of thymidine phosphorylase genetic variation on the prognosis of Her2 negative metastatic breast cancer patients treated with capecitabine based first line chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1002-1008.
[15]	LIU Yujia, LI Li, HU Xiaoping, ZHONG Like, LI Jingjing, HUANG Ping, ZHANG Yiwen. A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 852-859.